Axl Kinase Inhibitor Pipeline Insight
DelveInsight’s, “AXL Kinase Inhibitor - Pipeline Insight, 2022,” report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in AXL Kinase Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
AXL Kinase Inhibitor Understanding
AXL Kinase Inhibitor: Overview
AXL (anexelekto) is a Receptor Tyrosine Kinase (RTK) belonging to the TAM family. It is a cell-surface transmembrane receptor that exerts regulated kinase activity through its cytoplasmic domain. Other members of the TAM family are Mer and Tyro3. AXL is widely expressed in many organs, such as macrophages, endothelial cells, heart, liver and skeletal muscle, where it plays a variety of roles, including clearing apoptotic material, regulating cell survival, maintaining vascular integrity, and hematopoiesis. The AXL receptor tyrosine kinase (RTK) is unique in that AXL gene alterations are rare, but AXL expression is upregulated on the cell surface in many cancer types, suggesting an advantage for cancer cells. GAS6/AXL signalling functions as an important pathway driving cancer cell survival, proliferation, migration and invasion, which makes AXL a potential target in cancer treatment. AXL's crucial role in both tumour biology and therapeutic resistance, makes it an attractive target for antineoplastic therapies. Therefore, targeting the AXL to inhibit its function might be a promising strategy for the treatment of various malignant tumors. Different strategies of targeting the AXL have already been considered.
"AXL kinase inhibitors - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the AXL kinase inhibitors pipeline landscape is provided which includes the disease overview and AXL kinase inhibitors treatment guidelines. The assessment part of the report embraces, in depth AXL kinase inhibitors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, AXL kinase inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence AXL kinase inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve AXL kinase inhibitors.
AXL kinase inhibitors Emerging Drugs Chapters
This segment of the AXL kinase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
AXL kinase inhibitors Emerging Drugs
Exelixis’ flagship compound cabozantinib is a targeted agent that inhibits the activity of receptor tyrosine kinases including MET, AXL, VEGF receptors and RET. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, and resistance to multiple therapies, including immune checkpoint inhibitors (ICIs). In the U.S., CABOMETYX tablets are approved for the treatment of patients with advanced RCC; for the treatment of patients with HCC who have been previously treated with sorafenib; for patients with advanced RCC as a first-line treatment in combination with nivolumab; and for adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer that has progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible. Cabozantinib is being developed by Exelixis/Ipsen and it is currently in Phase III for Non-Small Cell Lung Cancer, Prostate Cancer, Hepatocellular Carcinoma, Differentiated Thyroid Cancer, and Renal Cell Carcinoma. Phase II for Bladder Cancer, Colorectal Cancer. Phase I/II for Advanced or Metastatic Solid Tumors. Phase I for Metastatic Genitourinary Tumors. Exelixis and Ipsen are together working on Cabozantinib for different indications.
Sitravatinib: Mirati Therapeutics/BeiGene
Sitravatinib is a spectrum-selective kinase inhibitor that inhibits receptor tyrosine kinases (“RTK”s), including TAM family receptors (TYRO3, Axl, Mer), split family receptors (VEGFR2, KIT) and RET. This is designed to overcome resistance to checkpoint inhibitor therapy, a common problem with most approved checkpoint inhibitors. The molecule is being investigated in a phase III trial as a combo in NSCLC following disease progression. Through its partner BeiGene, the molecule is also being investigated in other solid tumors. Mirati Therapeutics is working on Non-Small Cell Lung Cancer (NSCLC) which is currently in Phase III of development and for Bladder Cancer. Beigene is working on advanced solid tumors and Hepatocellular Carcinoma, Gastric/Gastroesophageal Junction Cancer, Advanced Biliary Tract Cancer which is currently in Phase II of development.
Batiraxcept is a therapeutic recombinant fusion protein that has been shown to neutralize GAS6 activity by binding to GAS6 with very high affinity in preclinical models. In doing so, batiraxcept selectively inhibits the GAS6-AXL signaling pathway, which is upregulated in multiple cancer types including ovarian, renal and pancreatic. In preclinical studies, GAS6-AXL inhibition has shown anti-tumor activity in combination with a variety of anticancer therapies, including radiation therapy, immuno-oncology agents, and chemotherapeutic drugs that affect DNA replication and repair. Increased expression of AXL and GAS6 in tumors has been correlated with poor prognosis and decreased survival and has been implicated in therapeutic resistance to conventional chemotherapeutics and targeted therapies. In ovarian cancer, increased GAS6 expression has been demonstrated. Batiracept is currently in Phase III for Platinum-resistant Ovarian Cancer, Phase II for Urothelial Carcinoma, Phase I/II for Clear Cell Renal Cell Carcinoma.
ONO-7475: Ono Pharmaceutical
ONO-7475 is being developed by Ono Pharmaceutical and it is currently in Phase I/II for Acute Leukemia and Myelodysplastic Syndromes, Phase Me for Advanced or Metastatic Solid Tumors. It acts as AXL receptor tyrosine kinase inhibitors, Proto-oncogene protein c-mer inhibitors. In company’s pipeline the product is in phase II stage of development.
Further product details are provided in the report……..
AXL kinase inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different AXL kinase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in AXL kinase inhibitors
There are approx. 22+ key companies which are developing the therapies for AXL kinase inhibitors. The companies which have their AXL kinase inhibitors drug candidates in the most advanced stage, i.e. Phase II include Exelixis/Ipsen.
DelveInsight’s report covers around 22+ products under different phases of clinical development like
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
AXL Kinase Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
AXL Kinase Inhibitor: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses AXL Kinase Inhibitor therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging AXL Kinase Inhibitor drugs.
AXL Kinase Inhibitor Report Insights
- AXL Kinase Inhibitor Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
AXL Kinase Inhibitor Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing AXL Kinase Inhibitor drugs?
- How many AXL Kinase Inhibitor drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for AXL Kinase Inhibitor?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the AXL Kinase Inhibitor therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for AXL Kinase Inhibitor and their status?
- What are the key designations that have been granted to the emerging drugs?